Tregs and rethinking cancer immunotherapy

Research output: Contribution to journalReview article

413 Scopus citations

Abstract

Tumors express antigens that should induce immune-mediated rejection, but spontaneous rejection of established tumors is rare. Recent work demonstrates that one reason for the lack of tumor rejection is that tumors actively defeat host immunity. This concept forces us to rethink current approaches to harnessing potent, specific host immunity to battle cancer, most of which are based on the paradigm that inducing more antitumor immune cells alone is therapeutic. However, as I discuss in this Personal Perspective, a newer paradigm predicts that reducing tumor-driven immune suppression will be clinically beneficial. CD4+CD25+ Tregs are one mechanism of tumor-driven immune evasion that provide prototypical targets for testing novel anticancer treatment strategies within the newer paradigm.

Original languageEnglish (US)
Pages (from-to)1167-1174
Number of pages8
JournalJournal of Clinical Investigation
Volume117
Issue number5
DOIs
StatePublished - May 1 2007

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Tregs and rethinking cancer immunotherapy'. Together they form a unique fingerprint.

  • Cite this